Commercially insured patients with deductibles and coinsurance pay more when manufacturers raise a drug’s list price and do not directly benefit from the confidential rebates paid by manufacturers to insurers, according to a study published this morning in JAMA Open Network.
The study was authored by clinicians affiliated with Brigham & Women’s Hospital and the Harvard School of Medicine. They examined how list and net prices changed for 79 brand name drugs that sold more than 1,000 units per quarter between 2015 and 2017. Although small in number, those drugs generated $67 billion in sales revenue in 2017, or nearly 15% of all expenditures on prescription drugs in the U.S.
Commercially insured patients with deductibles and coinsurance pay more when manufacturers raise a drug’s list price and do not directly benefit from the confidential rebates paid by manufacturers to insurers, according to a study published this morning in JAMA Open Network.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
